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Summary Carcinoma of unknown primary site (CUPS) accounts for 5-10% of all malignancies. Forty patients with metastatic CUPS or
advanced oesophagogastric/pancreatic adenocarcinomas were recruited. Eligibility included ECOG performance status 0-2, minimum life
expectancy of 3 months and measurable disease. The regimen consisted of bolus intravenous 5 fluorouracil (5-FU) and leucovorin (20 mg
m-2) days 1-5 and carboplatin (AUC5) on day 3. The leucovorin/carboplatin/5-FU (LCF) was repeated every 4 weeks. The starting dose of 5-
FU was 350 mg m-2 day-' with escalation to 370 and then 400 mg m-2 day-' after the toxicity at the previous level had been assessed. The
maximum tolerated dose (MTD) was defined as the dosage of 5-FU that achieved 60% grade 3/4 toxicity. In addition, objective and
symptomatic responses, quality of life and survival were assessed. The MTD of 5-FU in the LCF regimen was 370 mg m-2. The predominant
toxicity was asymptomatic marrow toxicity. The 350 mg m-2 level was then expanded. There were two toxic deaths due to neutropenic sepsis,
one at 370 mg m-2 after one course and one at 350 mg m-2 after four courses. The objective response rate was 25% with one complete
response (CR) and nine partial responses (PRs). The median duration of response was 3.4 months (range 1-10). The CR and eight of the
nine PRs were in CUPS patients. Twelve patients developed progressive disease on LCF. Median survival for all 40 patients was 7.8 months
(10 months median survival for those treated at 350 mg m-2). The majority of patients described a symptomatic improvement with LCF
chemotherapy. The recommended dose of 5-FU forfuture studies is 350 mg m-2 combined with leucovorin 20 mg m-2 and carboplatin (AUC5).
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Carcinoma ofunknown primary site (CUPS) accounts for between
5% and 10% ofall patients presenting with a malignancy (Moertel
et al, 1972; Stewart et al, 1979). Initially such patients were
believed to have a poorprognosis. However, a recent retrospective
analysis of 48 patients by Pavlidis et al (1992) suggests that
CUPS is in fact a very heterogeneous group of diseases and that
certain tumour subgroups are highly responsive to platinum-
based chemotherapy. The favourable subgroups include tumours
expressing neuroendocrine elements, epidermoid tumours of the
cervical lymph nodes, women with lone axillary node adenocarci-
noma or predominantly diffuse peritoneal carcinomatosis and
undifferentiated carcinomas of the midline structures (referred to
as the 'extragonadal germ-cell cancer syndrome') (Copeland and
McBride, 1973; Richardson et al, 1981; Mobit-Tabatabai et al,
1986; Hainsworth et al, 1988; Strnad et al, 1989).
It has been suggested that the ideal combination chemotherapy
for CUPS would include the optimum treatment for as broad
a range oftumour types as possible. Hainsworth et al (1988, 1992)
reviewed 220 patients with poorly differentiated carcinoma or
adenocarcinoma treated with platinum-based chemotherapy
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between 1978 and 1989 at Vanderbilt University, Nashville, TN,
USA. Twenty-six per cent of patients achieved a complete
response (CR) and 36% a partial response (PR). Actuarial 12-year
survival was 16%. The authors advocate a trial of platinum
chemotherapy in all patients with poorly differentiated carcinoma
or adenocarcinoma of unknown primary site. Establishing the
existence of a primary ovarian tumour in a woman with peritoneal
carcinomatosis can be problematic and in such circumstances it is
recommended that the patient receive systemic or intra-peritoneal
platinum-based chemotherapy (Muggia and Baranda, 1993). 5-
Fluorouracil (5-FU) has activity in upper and lower gastroin-
testinal malignancies, breast and pancreatic tumours. Bolus 5-FU
in combination with leucovorin over 5 days is currently regarded
by many as the optimum schedule for gastrointestinal malignan-
cies (Machover et al, 1986). In this trial 5-FU was given by the 5-
day schedule. Low-dose leucovorin was chosen based on the work
of Poon et al (1991), which established (at least in colorectal
cancer) that it is not necessary to use higher doses ofleucovorin to
enhance the therapeutic efficacy of 5-FU. It is reasonable to
combine 5-FU and leucovorin with a platinum agent to achieve as
wide a spectrum ofactivity over as many tumour types as possible.
As it was believed that this regimen would have activity in inoper-
able pancreatic and oesophagogastric carcinomas such patients
were also included in the trial. Carboplatin was used in preference
to cisplatin in view of its lower incidence ofassociated neurotoxi-
city, ototoxicity and emetogenesis (Calvert et al, 1982).
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The primary aims ofthe study were to determine the maximum
tolerated dose (MTD) of 5-FU in the leucovorin/5-FU/carboplatin
combination (LCF) and investigate the patterns of dose-related
toxicity. The secondary aims were to assess the objective response
rates, symptomatic response, quality oflife and survival.
METHODS
Forty patients with histologically proven CUPS or inoperable
pancreatic/oesophagogastric adenocarcinoma were recruited at the
Royal Marsden Hospital. Patients were required to be of ECOG
performance status (PS) 0-2 (Oken et al, 1982), with a minimum
life expectancy of3 months and have bidimensionally measurable
disease.
A haematological and biochemical screen was performed for all
patients, including liver function tests and serum tumour markers
(AFP, beta-HCG, CEA, CA125, CA19-9). In addition, all patients
were assessed radiologically by chest radiograph, computerized
tomography (CT) scan of thorax, abdomen and pelvis and in
females mammogram and pelvic ultrasound. Upper and lower
gastrointestinal tract endoscopy was performed if possible.
Patients in whom tumour markers and imaging techniques
revealed a primary tumour were ineligible for the trial (other than
inoperable oesophagogastric and pancreatic adenocarcinomas).
Renal function pretreatment was assessed by creatinine clearance
and this was repeated after alternate courses of chemotherapy.
All patients were asked to provide written consent to enter the
study, which was approved by the Committee for Clinical
Research and Ethics.
Chemotherapy regimen
The regimen consisted of bolus intravenous 5-FU and leucovorin
(20 mg m-2) on days 1-5 and carboplatin (AUC5) on day 3
(Calvert et al, 1989). The chemotherapy regimen was repeated
every 4 weeks. The starting dose of 5-FU was 350 mg m-2. This
Table 1 Patient characteristics
Characteristic Number %










CEA (n=37) 22 59
CA199 (nr25) 13 52
CA125 (nr19) 13 68
HCG (n=36) 4 11
AFP (n=35) 2 6





was increased to 370 mg m-2 and subsequently to 400 mg m-2. The
dose of5-FU was escalated after 5-6 patients had received at least
one cycle oftreatment at each dose level. The dose ofcarboplatin
was calculated before each course, using the most recent creati-
nine clearance result.
Antiemetic prophylaxis consisted of 8 mg of dexamethasone
given i.v. at the time ofthe carboplatin administration followed by
2 days oforal dexamethasone (4 mg tds) and metoclopramide (10
mg tds). Ice was sucked by the patient for 30 min, commencing 5
minbefore the administration of5-FU, in an attempt to reduce oral
mucositis.
Toxicity
All patients were evaluated after each course ofchemotherapy for
toxicity using the World Health Organization guidelines (Miller et
al, 1981). Interim analyses oftoxicity were performed after every
5-6 patients had been recruited and received at least one course
each. These analyses of chemotherapy-induced toxicity (worst
toxicity for all cycles per patient) were then used to determine the
MTD of5-FU in the regimen. This was defined as the dosage of5-
FU that resulted in 60% grade 3/4 toxicity. Leucopenia, thrombo-
cytopenia, diarrhoea and mucositis were identified as the most
important side-effects to follow, being well-recognized side-
effects of 5-FU. (mucositis: grade 2,25% reduction; grade 3/4,
50% reduction; diarrhoea: grade 2, 25%; grade 3, 50%; grade 4,
75%; plantar-palmar erythema grade 2/3, 25%; grade 4, 50%). If
the total WBC was less than 1.5 on day 1, or less than 0.5 on day
21 a 25% dose reduction of 5-FU was made and the next course
was delayed 2 weeks. Carboplatin doses were amended according
to the latest creatinine clearance test. Following determination of
the MTD it was planned to enter subsequent patients at the level
below the MTD to gain further experience in terms of toxicity,
objective response rates, survival and symptomatic improvement.
Assessment
Patients were treated to maximum radiological response (as
assessed by WHO criteria) (Miller et al, 1981). The CT scan was
repeated after the third and sixth courses of chemotherapy.
Responsive or stable disease with acceptable toxicity after three
courses was an indication to continue. Afterthe sixth course, treat-
ment was stoppedunless there was evidence ofcontinued response
to treatment between courses 3 and 6. Patients received a
Table 2 Histopathology
Tumour type Number
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Table 3 Analyses of toxicity
Dose of 5-FU No. of patients Total Grade 3/4 Grade 3/4 Grade 3/4 Grade 3/4
(mg m-2) grade 3/4(%) leucopenia (%) platelets(%) diarrhoea (%) mucositls (%)
350 5 40 20 0 20 0
370 6 66.6 33 50 17 0
400 2 100 100 50 50 50
maximum of eight courses. If clinical or radiological progressive
disease became apparent at any stage then treatment was stopped.
Before administration of each course of LCF patients were inter-
viewed by the research nurse who graded and recorded toxicity
and documented symptomatic improvements. All patients were
asked to complete an EORTC QL core 30 quality oflife question-
naire before chemotherapy, and after courses 3, 6 and 8 as applic-
able (Aaronson et al, 1993).
RESULTS
Forty patients were recruited, 30 with CUPS, nine with inoperable
oesophagogasatric adenocarcinoma and one with inoperable
pancreatic adenocarcinoma. The median age was 59 years (range
31-74). Twenty-three patients were men (57.7%) and 17 women
(42.5%) (Tables 1 and 2). Three patients had previous chemo-
therapy: two with epirubicin-cisplatin-fluorouracil and one with
methotrexate. One patient was PS 2 when assessed for trial eligi-
bility (in the outpatient clinic) but PS 3 on receiving the first
course ofLCF. He was included in the analysis as he was eligible
at the time of trial entry. The median number of courses of LCF
delivered was 4 (range 1-8).
Toxicity and MTD
The first five patients received 5-FU at 350 mg mr-2day-' for a total
of 15 courses. The incidence ofgrade 3/4toxicity was 40%, halfof
which was asymptomatic bone marrow toxicity (Table 3). The
dose was therefore escalated to the next dose level, 370 mg m-2.
Six patients were treated atthis level with 66.6% grade 3/4 toxicity
(50% asymptomatic marrow toxicity, and 16.6% non-marrow toxi-
city). Although by toxicity definition the MTD had been reached,
as the majority ofthe toxicity was accounted for by asymptomatic
marrow toxicity it was decided to escalate to the third dose level,
400 mg m-2. Two patients were entered andreceived one course of
LCF. At this stage one patient from level 2 (370 mg m-2) died of
neutropenic sepsis. In discussion with the Research Ethics
Committee it was decided that all current patients should be
treated at 350 mg m-2 and that this level should be expanded to
gain greater experience. The MTD of 5-FU in LCF was therefore
determined as 370 mg m-2. It was noted that the patient who died
had grade 2 leucopenia but grade 4 neutropenia. On reviewing the
neutrophil counts in all patients already on treatment, it was
found that at 350 mg m-2 there was 20% leucopenia, but 40%
neutropenia. At 370 mg m-2 there was 16.6% leucopenia, but 50%
neutropenia. Thereafter, the neutrophil count was included in the
assessment oftoxicity.
In all, 32 patients received 350 mg m-2 5-FU with 68.7% experi-
enceing grade 3/4 toxicity (worst toxicity for all cycles per patient)
for at least one category during their treatment (including neutro-
penia). Haematological toxicity (neutropenia 59%,thrombocytopenia
12.5%), diarrhoea(6%) andmucositis (9%) werethemostfrequently
noted side-effects. A second toxic death occurred in a patient with
neutropenic sepsis and diarrhoea after his fourth course of LCF at
350 mgm-2.
Of the 32 patients treated at 350 mg in-2, ten (31%) required a
25% dose reduction of5-FU, nine (28%) a 50% dose reduction and
three (9%) had to miss one course owing to toxicity. Six patients
were initially entered to receive 370 mg m-2 5-FU. As one died a
toxic death the other five were reduced to 350 mg m-2. Two of
these patients required a 50% dose reduction of 5-FU, and two a
25% dose reduction for toxicity. Both patients started at 400 mg
m7-2were automatically reduced to 350 mg m7-2afterthe toxic death,
in addition to 50% reductions of 5-FU because of toxicity. No
reductions in leucovorin were made. Five patients had a reduced
carboplatin dosage based on a fall in theircreatinine clearance.
Symptomatic responses
The LCFregimen demonstrates good improvement for a variety of
patient symptoms. Symptomatic responses were observed in two
of four patients with dysphagia (50%), 11 of 14 patients with
reflux (79%), 17 of24 patients with pain (71%), 11 of 19 patients
with anorexia (57%), 12 of 15 patients with nausea (80%), five of
eight patients with vomiting (63%) and seven ofnine patients with
altered bowel habit (78%); 18 of21 patients gained weight (86%).
Two patients each with dyspnoea and lethargy did not experience
improvement.
Objective responses
Of the 40 patients, ten (25%) had an objective response with one
(2.5%) complete response (CR) andnine (22.5%) partial responses
(PRs). The CR occurred in a female patient with undifferentiated
CUPS and elevated CA125. Eight of the nine PRs occurred
in patients with CUPS and the other in a patient with oesopha-
gogastric adenocarcinoma. Two patients died before clinical or
radiological response couldbe assessed (one toxic death, one cere-
brovascular accident with normal blood counts). They were
considered to be non-responders. Five of nine (55%) CUPS
responders had poorly differentiated adenocarcinoma or undiffer-
entiated carcinoma. The remaining four responders had moder-
ately differentiated adenocarcinoma. Six ofnine CUPS responders
were female (66.6%). Five ofthe six women (83.3%) had a raised
CA125. Of the nine CUPS responders four (44.4%) had an
elevated CEA and three (33.3%) an elevated CAl9-9.
Twelve patients developed progressive disease (PD) while
receiving chemotherapy (ten CUPS, one pancreatic adenocarci-
noma and one oesophagogastric adenocarcinoma). The one patient
who attained CR had a disease-free interval of 6.7 months before
relapsing. Median duration of response for the ten responders to
LCF was 3.4 months (range 1-10).
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Quality of life
Thirty-two patients completed a baseline questionnaire, 16 after
the third course, and four after the sixth course. The reduced
numbers after courses 3 and 6 reflect the relatively few patients
who proceeded to that number of chemotherapy cycles. The data
were analysed using a Wilcoxon matched-pairs signed-ranks test.
No statisically significant improvement or deterioration of quality
of life could be shown.
Survival
Median survival for all 40 patients was 7.8 months. The patients
who received 350 mg m-2 5-FU had 10-month median survival
with 40.4% probability of 1-year survival. Median survival was
4 months for the 370 mg m-2 group and 2.2 months for the
400 mg m-2 group. Median time offollow-up (recorded for the 18
surviving patients) was 8.3 months (range 2.8-16.6).
DISCUSSION
The MTD of 5-FU in the LCF regimen was identified as 370 mg
m-2. In addition, this series of 40 patients (30 with CUPS) treated
with leucovorin-carboplatin-5-fluorouracil demonstrated an
overall objective response rate of25% (one CR and nine PRs). For
the 30 patients with CUPS there was one CR (3%) and eight PRs
(27%), with a total objective response rate of 30%. The one
remaining PR occurred in a patient with an advanced oesopha-
gogastric adenocarcinoma. A recent phase II study ofcisplatin, 5-
FU and leucovorin with 27 evaluable patients gave very similar
results to those with LCF (Lenzi et al, 1993). It demonstrated a
30% response rate, one CR and seven PRs. The authors reported
only modest leucopenia, although they commented that 6 of 27
patients developed a neutrophil count < 500 mm-3 (similar to grade
4 toxicity).
In the current series at 350 mg m-2 5-FU there was 28% grade
3/4 leucopenia, but 59% neutropenia. Initially, the protocol for
dose reduction of 5-FU was dependent on the WBC and not
neutrophils. In view ofthe findings ofthe interim analyses and the
two deaths from neutropenic sepsis, the neutrophil count was
subsequently used in addition to the WBC in determining the
necessity for a dose reduction. Toxicity other than haematological
at the MTD was modest (16.6% grade 3/4 diarrhoea, no grade
3/4 mucositis). This suggests that LCF is a safe regimen providing
that the neutrophil count is carefully monitored and the dosage
of 5-FU reduced accordingly. One of the two toxic deaths
occurred after the patient had received four cycles of chemo-
therapy at 350 mg m-2 5-FU, which may have been a reflection
ofcumulative toxicity.
As previously discussed there are certain subgroups who will
respond to chemotherapy. In this study, five ofnine CUPS respon-
ders (55.5%) had poorly differentiated adenocarcinoma or undif-
ferentiated carcinoma.
Four groups have investigated platinum-based regimens in
CUPS (all used cisplatin). The Vanderbilt series of 220 patients
included predominantly poorly differentiated carcinoma or adeno-
carcinoma histology plus 16 patients with other poorly differenti-
ated tumours (Hainsworth et al, 1992). Their CR rate was 26% and
PR 36%. However, most of their patients were young with good
PS (85% PS 0-1) compared with a median age of 59 years and
only 50% being PS 0-1 in the LCE trial. Also, 54 of 220 patients
(25%) in the Vanderbilt series were felt to have extragonadal
germ-cell cancer syndrome. Inclusion ofthis favourable subgroup
of patients in addition to the exclusion ofolder, poor performance
status patients and well-differentiated carcinomas may have
contributed to the high response rate found by the Vanderbilt
series. Of note, the Vanderbilt patients presented between 1978
and 1989, a period during which immunocytochemistry tech-
niques for improved diagnosis were still evolving. In fact a retro-
spective histological review suggested that six patients had
lymphoma rather than carcinoma (Hainsworth et al, 1992).
Van der Gaast et al (1990) used a platinum regimen in 40
patients with poorly differentiated carcinoma/adenocarcinoma and
demonstrated 53% objective response rate with 12% CR. Again,
the lack of inclusion of well-differentiated and moderately differ-
entiated tumours probably favourably influenced the results. Two
studies Raber et al (1991) and Pavlidis et al (1992) reported CR
rates of 11% and 16%, respectively, for CUPS patients with plat-
inum regimens (histology included well-differentiated and
moderate and poorly differentiated tumours).
This trial demonstrates that LCF is as effective as other plat-
inum-based chemotherapy regimens for patients with CUPS with
good symptomatic improvement and no deterioration ofquality of
life. The MTD of 5-FU in LCF has been identified and the
predominant toxicity is haematological. LCF has the advantage
of being administered in the outpatient setting as intravenous
hydration is not required. LCF merits further phase II evaluation in
patients with carcinoma ofunknown primary site.
REFERENCES
Aaronson NK, Ahmedzais S, Bergman B, Cull A, Duez NJ, Filiberti A, Flechtner H,
Fleischman SB and de Haes JC (I1993) The European Organisation of Research
and Treatment ofCancer QLQ-C30: a quality-of-life instrument for use in
international clinical trials in oncology. JNatl Cancer Inst 85: 365-376
Calvert AH, Harland SJ, Newell DR, Siddik ZH, Jones AC, McElwain TJ, Raju S,
Wiltshaw E, Smith IE, Baker JM, Peckham MJ and Harrap KP (1982) Early
Clinical Studies with cis-diammine-1, 1-cyclobutanediacarboxylate platinum
II. Cancer Chemother Pharnacol 9: 140-147
Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik
ZH, Judson IR, Gore ME and Wiltshaw E (1989) Carboplatin dosage:
prospective evaluation of a simple formula based on renal function. J Clin
OncoI7: 1748-1756
Copeland EM and McBride CM (1973) Axillary metastases from unknown primary
sites. Ann Surg 178: 25-27
Hainsworth JD, Johnson DH and Greco FA (1988) Poorly differentiated
neuroendocrine carcinoma of unknown primary site: a newly recognized
clinicopathologic entity. Ann Intern Med 109: 364-371
Hainsworth JD, Johnson DH and Greco FA (1992) Cisplatin-based combination
chemotherapy in the treatment ofpoorly differentiated carcinoma and poorly
differentiated adenocarcinoma on unknown primary site: results of a 12-year
experience. J Clin Oncol 10: 912-922
Lenzi R, Raber MN, Frost P, Schmidt S and Abbruzzese JL (1993) Phase 11 study of
cisplatin, 5-fluorouracil and folinic acid in patients with carcinoma of unknown
primary origin. Eur JCatncer 29A: 1634
Machover D. Goldschmidt E, Chollet P, Metzer G, Zittoun J, Marquet J,
Vanderbulcke J-M, Misset J-L, Schwarzenberg L, Fourtillan JB, Gaget H and
Mathe G (1986). Treatment of advanced colorectal and gastric
adenocarcinomas with 5-fluorouracil and high dose folinic acid. J Clin Oncol
4: 685-696
Miller AB, Hoogstraten B, Staquet M and Winkler A (1981) Reporting results of
cancer treatment. Cancer 47: 207-214
Mobit-Tabatabai MA, Dasmahapatra KS, Rush BF Jr and Ohanian M (1986)
Management of squamous cell carcinoma of unknown origin in cervical lymph
nodes. Am JSurg 52: 152-154
Moertal CG, Reitmeier RJ, Schutt AJ and Hahn RG (1972) Treatment of the patient
with adenocarcinoma of unknown origin. Cancer 30: 1469-1472
Muggia FM and Baranda J (1993) Management ofperitoneal carcinomatosis of
unknown primary tumor site. Semin Oncol 20: 268-272
British Journal of Cancer (1997) 75(1), 101-105 C Cancer Research Campaign 1997LCFin carcinoma ofunknown primary 105
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFaddon El and
Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative
Oncology Group. Am J Clin Oncol 5: 649-655
Pavlidis N, Kosmidis P, Skarlos D, Briassoulis E, Beer M, Theoharis D, Bafaloukis
D, Maraveyas A and Fountzilas G (1992) Subsets oftumors responsive to
cisplatin or carboplatin combinations in patients with carcinoma of unknown
primary site. Ann Oncol 3: 631-634
Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt
R, Kardinal CG and Mailliard JA (1991) Biochemical modulation of
fluorouracil with leucovorin: confirmatory evidence of improved therapeutic
efficacy in advanced colorectal cancer. J Clin Oncol 11: 1967-1972
Raber MN, Faintuch J, Abbruzzese J, Sumrall C and Frost P (1991) Continuous
infusion 5-fluorouracil, etoposide and cis-diammine-dichloroplatinum in
patients with metastatic carcinoma of unknown primary site. Anti Onicol 2:
519-520
Richardson RL, Schoumacher RA, Fer MF, Hande KR, Forbes JT, Oldham RK and
Greco FA (1981) The unrecognised extragonadal germ cell cancer syndrome.
Ann Intern Med 94: 181-186
Stewart JF, Tattersall MHN, Woods RL and Fox RM (1979) Unknown primary
adenocarcinoma: incidence ofoverinvestigation and natural history. Br MedJ
1: 1530-1533
Stmad CM, Grosh WW, Baxter J, Burnett LS, Jones HW Greco FA and Hainsworth
JD (1989) Peritoneal carcinomatosis ofunknown primary site in women. Ann
Intern Med 111: 213-217
Van der Gaast A, Verweij J, Henzen-Logmns SC, Rodenburg CJ and Stoter G (1990)
Carcinoma of unknown primary: indentification of a treatable subset. Ann
Oncol 1: 119-123.
C Cancer Research Campaign 1997 British Journal ofCancer (1997) 75(1), 101-105